Role of Pulsatile Hemodynamics in Acute Heart Failure: Implications for Type 1 Cardiorenal Syndrome

Shih-Hsien Sung\textsuperscript{a, c, d} Chen-Huan Chen\textsuperscript{b–d}

Departments of \textsuperscript{a}Medicine and \textsuperscript{b}Medical Research and Education, Taipei Veterans General Hospital, and \textsuperscript{c}Department of Medicine, and \textsuperscript{d}Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan, ROC

Key Words
Acute heart failure syndrome · Cardiorenal syndrome · Vascular aging · Pulsatile hemodynamics

Abstract
Heart failure has become a major health problem worldwide with a substantial financial burden mainly from hospitalization due to acute heart failure syndrome (AHFS). A considerable number of patients hospitalized for the treatment of AHFS experience significant worsening of renal function, which is now recognized as type 1 cardiorenal syndrome (CRS) and is associated with worse outcomes. Currently known risk factors for acute CRS in AHFS include obesity, cachexia, hypertension, diabetes, proteinuria, uremic solute retention, anemia, and repeated subclinical acute kidney injury events. Venous renal congestion due to hemodynamic changes also contributes to type 1 CRS. Vascular aging and its aggravated pulsatile hemodynamics have been shown to be involved in the pathogenesis of AHFS. Suboptimal recovery of the perturbation of the pulsatile hemodynamics may predict 6-month post-discharge cardiovascular outcomes in patients hospitalized due to AHFS. Furthermore, on-admission pulsatile hemodynamics may also be helpful to identify and stratify patients with aggravated pulsatile hemodynamics who may benefit from customized therapy. There are close interplays and feedback loops between heart and kidney dysfunction. Increased arterial stiffness accelerates pulse wave velocity and causes an earlier return of the reflected wave, resulting in higher systolic, lower diastolic, and higher pulse pressure in the central aorta and renal arteries. Increased pulsatile hemodynamics have been associated with deterioration of renal function in subjects with a high coronary risk and patients with hypertension or chronic kidney disease. Thus, there is a potential role of vascular aging/pulsatile hemodynamics in the pathophysiological pathways of acute CRS in AHFS.

Chen-Huan Chen, MD
Department of Medical Research and Education
Taipei Veterans General Hospital
No. 201, Sec. 2, Shih-Pai Road, Taipei, Taiwan (ROC)
E-Mail chench@vghtpe.gov.tw
**Introduction**

Heart failure (HF) affects over 5 million Americans and 15 million Europeans and is a major health problem worldwide [1, 2]. The cost in the United States is over USD 34 billion per year, mainly related to hospitalizations, with similar financial burdens for many European countries [2, 3]. The incidence of HF increases sharply with age, and survival is dismal following the development of HF [4]. Optimal treatment of this disabling and fatal condition may require functional characterization of the failed left ventricle (LV) and its interaction with the arterial system [5].

Over the past decades, it has been demonstrated that there are close interplays and feedback loops between heart and kidney dysfunction. The kidneys are recognized as one of the organs that receive abundant blood supply. As much as 20% of cardiac output constitutes the renal blood flow, >90% of which is distributed to the renal cortex to maintain a high and stable glomerular filtration rate (GFR). There are efficient mechanisms of autoregulation in the cortex so that renal blood flow and GFR remain constant in the face of large variations in systemic blood pressure (BP) [6]. However, renal impairment in patients with HF is common and increasingly recognized as an independent risk factor for morbidity and mortality [7]. The Acute Decompensated Heart Failure National Registry (ADHERE), a large database of 105,388 patients with HF requiring hospitalization in the United States, reported that 30% of the patients had an additional diagnosis consistent with chronic kidney disease (CKD) [8]. Several studies have established that >70% of the patients experience some increase in their creatinine (Cr) level during hospitalization for HF, with approximately 20–30% of HF patients experiencing an increase of >0.3 mg/dl [9, 10]. Any change in Cr has been shown to be associated with longer length of stay, increased costs, and increased short-term and long-term mortality [9–11]. However, the degree of Cr rise during the treatment of acute heart failure syndrome (AHFS), defined as new-onset or gradually or rapidly worsening HF signs and symptoms requiring urgent therapy [12], has a highly variable effect on mortality that is dependent on the population studied [13, 14].

**Heart Failure and Vascular Aging**

In subjects without HF, arterial load is increased among those with hypertension and is matched by increased end-systolic LV stiffness [15]. Increased end-systolic LV stiffness may be mediated by enhanced myocardial contractility or processes that increase passive myocardial stiffness, the latter may be responsible for the progression to preserved ejection fraction (EF) HF [15]. In patients with HF and impaired LV contractility, the ventriculoarterial coupling describes the efficiency of mechanical energetic transfer from the heart to the arteries [16]. Failure of an LV invariably generates reduced mechanical energy, and the efficiency of the transfer of the limited energy depends critically on whether or not the arterial tree is optimally adjusted to reduce loadings from its various segments. On the other hand, the ventriculoarterial coupling implies that afterloads generated from the various anatomical or physiological segments of the arterial tree may have an impact on the various components of the mechanical function of the failed LV during systole or diastole and may thus be involved in the deterioration of and decompensation into AHFS requiring hospitalization.
Acute Heart Failure Syndrome and Vascular Aging

Over the past two decades, there have been significant advances in the treatment of chronic reduced EF HF with the application of drugs blocking the major neurohormonal responses to the initial injury as well as of cardiac devices such as biventricular pacing rectifying the abnormal conduction and contraction in a failed LV. However, HF remains associated with a persistently high mortality and morbidity. The post-discharge mortality and re-hospitalization rates for AHFS reach 10–20 and 20–30%, respectively, within 3–6 months [17, 18]. We have also shown that about one third of the patients ever been admitted for AHFS would have post-discharge adverse events within 6 months [19]. While the majority of the patients appear to respond well to initial therapies consisting of loop diuretics and vasoactive agents, the management of AHFS is challenging given the heterogeneity of the patient population [12, 17, 18], absence of a universally accepted definition, incomplete understanding of its pathophysiology, and lack of robust evidence-based guidelines. Furthermore, the hospitalization for AHFS per se is one of the most important predictors for post-discharge mortality and readmission in patients with chronic HF [20, 21].

Coronary artery disease (CAD), hypertension, valvular heart disease, and/or atrial fibrillation, as well as noncardiac conditions such as renal dysfunction, diabetes, anemia, and medications (for example, nonsteroidal anti-inflammatory drugs and/or glitazones) may contribute to the occurrence of AHFS [2, 12]. Early vascular aging, a well-known cardiovascular risk factor, usually manifests as increased arterial stiffness, wave reflection phenomenon, central BP, carotid intima-media thickness, and endothelial dysfunction [22]. Aortic pulse wave velocity (PWV) is the well-acknowledged gold standard measurement of aortic stiffness associated with cardiovascular mortality and morbidity in patients with hypertension or diabetes and in the elderly [23–25]. In addition, the wave reflection phenomenon and the local assessments of arterial stiffness such as distensibility, compliance, elastic modulus, and β stiffness index may also provide prognostic information. In brief, vascular aging impairs cardiac function through aggravated pulsatile hemodynamics and is associated with the development and the progression of HF [19, 26].

We have investigated the interval changes of pulsatile hemodynamics in patients hospitalized for AHFS [19]. We found that pulsatile hemodynamics result mainly from arterial stiffening and the wave reflection phenomenon, and both may be involved in the pathogenesis of AHFS. Suboptimal recovery of pulsatile hemodynamics may predict 6-month post-discharge cardiovascular outcomes in patients hospitalized for AHFS. While pre- or post-discharge pulsatile hemodynamics indicate the completeness of treatment for AHFS, on-admission pulsatile hemodynamics may also be helpful to identify and stratify patients with aggravated pulsatile hemodynamics who may benefit from customized therapies. Our further work have disclosed that on-admission measures of wave reflection intensity, including carotid augmented pressure, Pb (amplitude of the backward pressure from a decomposed carotid pressure wave), and carotid pulse pressure (PP), may be useful for predicting long-term outcomes in AHFS patients with either systolic HF or preserved EF HF [27]. The results support a major role of vascular aging/pulsatile hemodynamics, increased wave reflections in particular, in the pathogenesis of AHFS [27].

Cardiorenal Syndrome

The phenomenon that HF is accompanied by renal failure is termed the cardiorenal syndrome (CRS) [28]. CRS has become a universal clinical challenge, implying both the development and worsening of renal insufficiency secondary to HF as well as harmful effects of
impaired renal function on the cardiovascular system [28]. CRS has recently been classified into five subtypes depending on the etiological and chronological interactions between cardiac and renal dysfunction (table 1) [28]. The mechanisms underlying CRS are multifactorial, including hemodynamic alterations, neurohormonal effects, and inflammation [29]. However, despite the increased awareness of CRS, further elucidation of its mechanisms and appropriate treatment approaches are clearly warranted. A substantial number of patients hospitalized for the treatment of AHFS experience significant worsening of renal function, which is associated with worse outcomes [29–31]. It remains unclear whether worsening renal function specifically contributes to poor outcomes or whether it is merely a marker of advanced cardiac and renal dysfunction [32].

CRS in AHFS is a particularly difficult condition to manage as treatment to relieve congestive symptoms of HF may lead to a further decline in renal function, which is a major independent predictor of long-term cardiac morbidity [30]. Several treatment strategies for decongestion in AHFS patients who develop CRS are currently under investigation, including invasive hemodynamic monitoring to guide therapy, use of continuous diuretic infusions, ultrafiltration, or novel therapies with adenosine or vasopressin receptor antagonists [33]. Surprisingly, in a randomized trial [30] involving patients hospitalized for AHFS, worsened renal function, and persistent congestion, the use of a stepped pharmacological therapy algorithm was superior to a strategy of ultrafiltration for the preservation of renal function at 96 h, with a similar amount of weight loss with the two approaches. Furthermore, ultrafiltration was associated with a higher rate of adverse events. Therefore, the underlying mechanisms of CRS in AHFS are complex and not fully understood [29, 31, 34]. Thus, there is a pressing need to continue the search for better strategies to manage acute CRS based on the new findings of its pathophysiology [34].

**Vascular Aging – The Link between the Heart and Kidneys**

BP measured at the central aorta is usually lower than BP measured at the brachial artery due to the progressive amplification of PP along the arterial tree [35]. PP amplification indicates the effectiveness of energy transfer and the augmentation by the locally reflected pressure wave, and, in addition, is an evaluation of arterial compliance [36–38]. Increased arterial stiffness accelerates PWV and causes an earlier return of the reflected wave, resulting in higher systolic BP, lower diastolic BP, and higher PP in the central aorta. Such changes in central hemodynamics would adversely have an impact on renal perfusion [39]. In normal individuals, the amplitude of wave reflection but not aortic PWV may be associated with filtration fraction and urinary albumin-creatinine ratio independently of systemic BP; both are signs of increased glomerular pressure [40]. In patients with a high risk of CAD, plasma

| Type 1 | Acute decompensated HF that leads to acute kidney injury |
|-------|---------------------------------------------------------|
| Type 2 | Chronic HF that leads to chronic kidney disease         |
| Type 3 | Acute kidney injury that leads to acute cardiac dysfunction such as arrhythmia or HF |
| Type 4 | Primary CKD contributes to cardiac dysfunction          |
| Type 5 | Secondary CRS, combined heart and kidney dysfunction due to systemic disorders such as sepsis and systemic lupus erythematosus |
Cr was significantly related to PP in the ascending aorta and the abdominal aorta on the level of renal arteries, and to aortic PWV [41]. In a cohort of 133 patients with CKD stages 3 and 4, aortic PWV was independently associated with the rate of change in renal function [42]. In another cohort of 145 CKD stage 3–5 patients, an independent association between brachial-ankle PWV and renal function decline and progression to commencement of dialysis or death was shown [43]. In addition to brachial-ankle PWV, LVEF was also negatively associated with the GFR slope, and higher brachial-ankle PWV and LVEF <40% were independently associated with progression to the renal end point [44]. Thus, central pulsatile hemodynamics may be a common basis for the associations among CKD, stroke, and CAD [39]. The underlying mechanism linking aortic stiffening and renal microvascular damage has been recently suggested by Hashimoto and Ito [36, 45]. In 133 patients with hypertension, central PP was closely related to changes in renal hemodynamics (resistive index of renal segmental artery) and urinary albumin excretion. It is likely that increased central PP causes renal microvascular damage through altered renal hemodynamics resulting from increased peripheral resistance and/or increased flow pulsation [36, 45].

**Perspective: Potential Role of Pulsatile Hemodynamics in Type 1 Cardiorenal Syndrome**

Based on the current understanding of the risk factors for acute CRS in AHFS, these include obesity, cachexia, hypertension, diabetes, proteinuria, uremic solute retention, anemia, and repeated subclinical acute kidney injury events [29]. In the hospitalized patient,
hemodynamic changes leading to venous renal congestion, neurohormonal activation, hypothalamic-pituitary stress reaction, inflammation and immune cell signaling, systemic endotoxemic exposure from the gut, superimposed infection, and iatrogenesis all may contribute to acute CRS [29]. However, the potential role of vascular aging/pulsatile hemodynamics in the pathophysiological pathways of acute CRS in AHFS has not been explored [29].

In perspective, we propose that vascular aging/pulsatile hemodynamics may be a major independent determinant of the deterioration of renal function and the development of CRS in patients with AHFS. We further hypothesize that CRS independently accelerates the clinical aggravation and development of post-discharge adverse events. The hypothetical framework is shown in figure 1. Future studies are definitely needed to prove the concept and expand our armament to target type 1 CRS.

Acknowledgments

This work was supported by a grant from the National Science Council (NSC 99-2314-B-010-034-MY3) and intramural grants (V99C1-091, V100C-145, V101C-092, VN99-01, VN100-01, and VN101-01) from the Taipei Veterans General Hospital, Taiwan, ROC.

Disclosure Statement

The authors have no conflicts of interest to declared.

References

1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstant MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:11977–2016.
2. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rannevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, ESC Committee for Practice Guidelines: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–1847.
3. Fang J, Mensah GA, Croft JB, Keenan NL: Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008;52:428–434.
4. Hugli O, Braun JE, Kim S, Pelletier AJ, Camargo CA Jr: United States emergency department visits for acute decompensated heart failure, 1992 to 2001. Am J Cardiol 2005;96:1537–1542.
5. Kameyama T, Asanoi H, Ishizaka S, Sasayama S: Ventricular load optimization by unloading therapy in patients with heart failure. J Am Coll Cardiol 1991;17:199–207.
6. Cowley AW Jr: Long-term control of arterial blood pressure. Physiol Rev 1992;72:231–300.
7. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudston ML: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1507–1592.
8. Adams KF Jr, Fonarow GC, Emerman CL, Legentel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP: Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209–216.
9. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Kruhholz HM: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61–67.
10. Nohria A, Lewis E, Stevenson LW: Medical management of advanced heart failure. JAMA 2002;287:628–640.
11. Weinfield MS, Chertow GM, Stevenson LW: Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999;138:285–290.

12. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L: Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958–3968.

13. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003;9:13–25.

14. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O’Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM: The prognostic im portance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136–141.

15. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM: Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;54:410–418.

16. Burkhoff D, Sagawa K: Venticular efficiency predicted by an analytical model. Am J Physiol 1986;250:R1021–R1027.

17. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC: Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76–84.

18. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB: Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768–777.

19. Sung SH, Yu WC, Cheng HM, Chuang SY, Wang KL, Huang CM, Chen CH: Pulsatile hemodynamics and clinical outcomes in acute heart failure. Am J Hypertens 2011;24:775–782.

20. Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell’Italia LJ, White M, Gheorghiade M: Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 2008;14:211–218.

21. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA: Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482–1487.

22. Nilsson PM, Boutouyrie P, Laurent S: Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension 2009;54:3–10.

23. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H, European Network for Non-invasive Investigation of Large Arteries: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588–2605.

24. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10–15.

25. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S, Pahor M, Bauer D, Newman A: Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;112:3958–3968.

26. Chae CU, Pfeffer MA, Glynn RJ, Mitchell EG, Taylor JO, Hennekens CH: Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999;281:634–639.

27. Sung SH, Yu WC, Cheng HM, Lee CW, Lin MM, Chuang SY, Chen CH: Excessive wave reflections on admission arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;112:3958–3968.

28. Ronco C, Haapiio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527–1539.

29. Ronco C, Cicoira M, McCullough PA: Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012;60:1031–1042.

30. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E: Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296–2304.

31. Tang WH, Mullens W: Cardiorenal syndrome in decompensated heart failure. Heart 2010;96:255–260.

32. Shah RV, Givertz MM: Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome. Curr Heart Fail Rep 2009;6:176–181.

33. Tang WH: Reconsidering ultrafiltration in the acute cardiorenal syndrome. N Engl J Med 2012;367:2351–2352.
O'Rourke MF, Safar ME: Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46:200–204.

Hashimoto J, Ito S: Pulse pressure amplification, arterial stiffness, and peripheral wave reflection determine pulsatile flow waveform of the femoral artery. Hypertension 2010;56:926–933.

Benetos A, Thomas F, Joly L, Blacher J, Pannier B, Labat C, Salvi P, Smulyan H, Safar ME: Pulse pressure amplification a mechanical biomarker of cardiovascular risk. J Am Coll Cardiol 2010;55:1032–1037.

Avolio AP, Van Bortel LM, Boutouyrie P, Cockcroft JR, McEniery CM, Pro¨togerou AD, Roman MJ, Safar ME, Segers P, Smulyan H: Role of pulse pressure amplification in arterial hypertension: experts’ opinion and review of the data. Hypertension 2009;54:375–383.

O'Rourke MF, Hashimoto J: Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007;50:1–13.

Fesler P, du Cailar G, Ribstein J, Mimran A: Glomerular hemodynamics and arterial function in normal individuals. J Hypertens 2010;28:2462–2467.

Temmar M, Jankowski P, Peltier M, Mouquet V, Debicka-Dabrowska D, Hamida F, Kawecka-Jaszcz K, Safar ME: Intraaortic pulse pressure amplification in subjects at high coronary risk. Hypertension 2010;55:327–332.

Ford ML, Tomlinson LA, Chapman TP, Rajkumar C, Holt SG: Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010;55:1110–1115.

Chen SC, Chang JM, Liu WC, Tsai YC, Tsai JC, Hsu PC, Lin TH, Lin MY, Su HM, Hwang SJ, Chen HC: Brachial-ankle pulse wave velocity and rate of renal function decline and mortality in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:724–732.

Chen SC, Lin TH, Hsu PC, Chang JM, Lee CS, Tsai WC, Su HM, Voon WC, Chen HC: Impaired left ventricular systolic function and increased brachial-ankle pulse-wave velocity are independently associated with rapid renal function progression. Hypertens Res 2011;34:1052–1058.

Hashimoto J, Ito S: Central pulse pressure and aortic stiffness determine renal hemodynamics: pathological implication for microalbuminuria in hypertension. Hypertension 2011;58:839–846.